Capricor’s latest quarterly filing details continued progress toward a pivotal FDA decision on Deramiocel, supported by strong Phase 3 clinical results demonstrating efficacy in Duchenne muscular dystrophy (DMD). The company’s business model hinges on an innovative cell therapy platform targeting muscle inflammation and fibrosis, differentiating it from gene-centric competitors. While facing regulatory and manufacturing scaling risks, Capricor’s orphan drug designations and unique product profile position it defensibly within a niche rare disease market. Upcoming catalysts include the August 2026 PDUFA date and manufacturing scale milestones.